IMV Executive Assistant
tel. (612) 624-1926
fax. (612) 625-1108
18-242 Moos Tower
515 Delaware St. SE
Minneapolis, MN 55455
BS California Institute of Technology
MD Columbia University
Kakuda TN, Page LM, Anderson PL, Henry K, Schacker TW, Rhame FS, Acosta EP,Brundage RC, Fletcher CV. Pharmacological basis for concenration-controlled therapy with zidovudine, lamivudine,and indinavir. Antimicrob Agents and Chemother 2001;45:236-42.
Chaloner K, Rhame FS. Quantifying and coumenting prior beliefs in clinical trials. Statistics in Medicine 2001;20:581-600.
Rhame, FS. Uncertain generalizability of switch studies (letter). CID 2003;36:1089
Rhame FS. Methicillin-resistant Staphylococcus aureus. [letter] Am J Med 1995;98:599-600.
Fletcher CV. Collier AC, Rhame FS, Bennett D, Para MF, Beatty CC, et al. Foscarnet for suppression of HIV replication. Antimicrob Agents Chemother 1994;38:604-7.
Little JW, Melnick SL, Rhame FS, Balfour HH Jr, Decher L, Rhodus NL,Merry JW, WalkerPO, Miller CE, Volberding P.
Prevalence of oral lesions in symptomatic and asymptomatic HIV patients. Gen Dentistry 1994;42:446-50.
Neaton JD, Wentworth DN, Rhame FS, Hogan C, Abrams DI, Deyton L. Considerations in choice of a clinical endpoint for AIDS clinical trials. Statistics in Medicine 1994;13:2107-25.
Noormohamed SE, Henry WK, Rhame FS, Balfour HH Jr, Fletcher CV. Strategies for control of zidovudine concentrations in serum. Antimicrob Agents Chemother 1995;39:2792-7
Rhame FS. FDA labeling requirements for disinfection of endoscopes: a counterpoint.[letter] Infect Control Hosp Epidemiol 1995;16:497.
Fletcher CV, Henry WK, Noormohamed SE, Rhame FS, Balfour HH Jr.The effect of cimetidine and ranitidine administration with zidovudine.Pharmacotherapy 1995;15:701-8.
Wells CL, Juni BA, Cameron SB, Mason KR, Dunn DL, Ferrieri P, Rhame FS. Stool carriage, clinical isolation, and mortality during an outbreak of vancomycin-resistant enterococci in hospitalized medical and/or surgical patients. Clin Infect Dis 1995;21:45-50.
Carlin BP, Chaloner KM, Louis TA, Rhame FS. Elicitation, monitoring, and analysis for and AIDS clinical trial. In: Case Studies in Bayesian Statistics (Gatsonis C, Hodges JS, Kass RE, Singpurinalland, eds.), Springer 1995.
Gunderson M, Mayo D, Rhame FS. Routine HIV testing of hospital patients and pregnant women: informedconsent in the real world. Kennedy Institute of Ethics Journal 1996;6:161-96.
Mildvan D, Bassiakos Y, Zucker ML, Hyslop N Jr, Krown SE, Sacks HS, Zachary J, Paredes J, Fessel WJ, Rhame F, et al.
Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection: ACTG 068. Antiviral Therapy 1996;1:77-88.
Saravolatz L, Neaton JD, Sacks L, Deyton L, Rhame F, Sherer R. CD4+ T lymphocyte counts and patterns of mortality among patients infected with human immunodeficiency virus who were enrolled in community programs for clinical research on AIDS. Clin Infect Dis 1996;22:513-20.
Michalova K, Moyes AL, Cameron S, Juni BA, Obritsch WF, Dvorak JA, Rhame FS. Povidone-iodine (Betadine) in the treatment of experimental Pseudomonas aeruginosa infectious keratitis. Cornea 1996;15:533-6.
Fletcher CV, Goodroad BK, Cummins LM, Henry K, Balfour HH Jr, Rhame FS. Pharmacokinetics of hyperimmune anti-human immunodeficiency virus I immunoglobulin in persons with AIDS. Antimicrob Agents Chemother 1997;41:1571-4.
Green LA, Rhame FS, Price RW, Perlman D, Capps L, Sampson J, Deyton L, Schnittman S, et al. Experience with a cross-study endpoint review committee for AIDS clinical trials. AIDS 1998;12:1983-90
Dobs AS, Cofrancesco J, Noltyen WE, Danoff A, Anderson R, Hamilton CD, Feinberg J,
Seekins D, Yangco B, Rhame F.
The use of transscrotal testosterone delivery system in the treatment of patients with weight
loss related to human immunodeficiency virus infection.
Am J Med 1999;107:126-32.
Rhame FS. Implications of market baskets, a pharmaceutical marketing practice [letter]. JAMA 1999;282:1134.
'Wisc-e-sota', a Joint UMN-UW Virology Training Grant Symposium was first held on Friday, Sepbember 20th, 2013 at the Uniiversity of Wisconsin-La Crosse, Cartwright Center. This was the inaugural collaborative symposium of the NIH T32-supported virology training programs at the University of Wisconsin-Madison and the University of Minnesota-Twin Cities. Talks and poster sessions were presented by students, postdocs and faculty. The second UMN-UW Virology Training Grant Symposium will be held in the Fall 2014. Details to follow.
The 2014 IMV Symposium will be held on May 12, 2014 and Mark Denison (Vanderbilt) and Bert Semler (UC-Irvine) will be the Keynote Speakers. Click on the link below to register and submit abstracts.
Read about bacteriophage phi 29 and why it matters.
Explore nearly a century's worth of discovery in the field of virology at the University of Minnesota.
"This Week in Virology" from professor Vincent Racaniello.